| Literature DB >> 29282123 |
Jin-Bor Chen1, Wen-Chin Lee1, Ben-Chung Cheng1, Sin-Hua Moi2, Cheng-Hong Yang3,4, Yu-Da Lin5.
Abstract
OBJECTIVES: To survey by measuring patient's functional status which is crucial when end-stage renal disease patients begin a dialysis program. The influence of the disease on patients can be examined by the measurement of Karnofsky Performance Status (KPS) scores, together with a quality of life survey, and clinical variables.Entities:
Keywords: Classification and regression tree approach; Functional status; Hemodialysis; Karnofsky Performance Status
Mesh:
Year: 2017 PMID: 29282123 PMCID: PMC5745856 DOI: 10.1186/s40001-017-0298-1
Source DB: PubMed Journal: Eur J Med Res ISSN: 0949-2321 Impact factor: 2.175
Baseline characteristics of the study population (N = 1166)
| Variables | Total | |
|---|---|---|
|
| SD | |
| Age (mean, SD) (years) | 60.87 | 12.05 |
| Treatment of year (mean, SD) | 7.87 | 5.78 |
| The number of HD a week (mean, SD) | 2.93 | 0.27 |
| Each dialysis time (mean, SD) (hours) | 3.91 | 0.24 |
| Dialyzer surface area (m2) | 2.16 | 0.25 |
| Gender ( | ||
| Male | 572 | 49.06 |
| Female | 594 | 50.94 |
| DM ( | ||
| No | 797 | 68.35 |
| Yes | 369 | 31.65 |
| Primary disease subclass ( | ||
| Glomerulonephritis | 279 | 23.93 |
| Systemic diseases | 641 | 54.97 |
| Obstructive nephropathy | 14 | 1.20 |
| Hemolytic uremic syndrome | 2 | 0.17 |
| Polycystic kidney disease | 16 | 1.37 |
| Others | 51 | 4.37 |
| Unknown cause | 162 | 13.89 |
| Use of vitamin D ( | ||
| No | 708 | 60.72 |
| Yes | 458 | 39.28 |
| Use of antihypertensive ( | ||
| No | 573 | 49.14 |
| Yes | 593 | 50.86 |
| Use of iron ( | ||
| No | 881 | 75.56 |
| Yes | 285 | 24.44 |
| Parathyroidectomy ( | ||
| No | 982 | 84.22 |
| Yes | 184 | 15.78 |
| Death ( | ||
| No | 1023 | 87.74 |
| Yes | 143 | 12.26 |
HD hemodialysis
P value for categorical variables were estimated by χ² test or Fisher's exact test
P value for continuous variables were estimated by independent two samples
Clinical features of the study population in-personvisit (N = 3509)
| Variable | Karnofsky score |
| |||
|---|---|---|---|---|---|
| Low ( | High ( | ||||
| Mean | SD | Mean | SD | ||
| Hb (g/dL) | 10.44 | 1.28 | 10.73 | 1.22 | < 0.001 |
| Hct (%) | 32.16 | 4.03 | 32.87 | 3.78 | < 0.001 |
| WBC (103/μL) | 6.28 | 1.90 | 6.11 | 1.70 | 0.014 |
| Albumin (g/dL) | 3.69 | 0.31 | 3.92 | 0.29 | < 0.001 |
| BUN (mg/dL) | 67.82 | 19.52 | 72.60 | 17.06 | < 0.001 |
| Creatinine (mg/dL) | 9.46 | 2.23 | 11.36 | 2.28 | < 0.001 |
| Ca (mg/dL) | 9.46 | 0.85 | 9.38 | 0.85 | 0.019 |
| P (mg/dL) | 4.78 | 1.45 | 5.11 | 1.43 | < 0.001 |
| Na (mEq/L) | 135.60 | 3.62 | 136.74 | 3.19 | < 0.001 |
| K (mEq/L) | 4.79 | 0.78 | 5.05 | 0.69 | < 0.001 |
| Glucose (mg/dL) | 164.26 | 62.92 | 131.15 | 52.04 | < 0.001 |
| AST (IU/L) | 19.41 | 7.21 | 19.00 | 7.05 | 0.149 |
| Alkaline P (IU/L) | 87.13 | 37.28 | 79.26 | 33.28 | < 0.001 |
| Cholesterol (mg/dL) | 172.13 | 37.97 | 174.69 | 37.29 | 0.088 |
| Triglyceride (mg/dL) | 153.68 | 91.33 | 150.11 | 91.50 | 0.329 |
| Uric acid (mg/dL) | 7.14 | 1.43 | 7.54 | 1.42 | < 0.001 |
| Ferritin (ng/mL) | 491.65 | 293.49 | 409.03 | 254.75 | < 0.001 |
| Al (μμg/dL) | 1.12 | 0.84 | 1.23 | 0.90 | 0.001 |
| iPTH (pg/mL) | 295.98 | 340.86 | 338.58 | 343.49 | 0.002 |
| Kt/V | 1.63 | 0.28 | 1.68 | 0.31 | < 0.001 |
| nPCR | 1.11 | 0.30 | 1.18 | 0.26 | < 0.001 |
| Ultrafiltration amount in each HD (L) | 1.92 | 1.21 | 2.23 | 1.29 | < 0.001 |
| Cardiothoracic ratio | 0.52 | 0.07 | 0.49 | 0.07 | < 0.001 |
P value for continuous variables were estimated by independent two samples
Karnofsky score: low < 80; high ≥ 80
Ferritin, Al, iPTH, Kt/V, nPCR, Cardiothoracic ratio expressed by medium values, others expressed by mean values
Hb hemoglobin, Hct hematocrit, Ca calcium, P phosphorus, Na sodium, K potassium, AST aspartate aminotransferase, Alkaline P alkaline phosphatase, Al aluminum, iPTH intact parathyroid hormone, nPCR normalized protein catabolic rate, HD hemodialysis
Fig. 1Classification tree for predicting Karnofsky Performance Status Scale in hemodialysis patients. TN: terminal node; *P value: P value for Fisher Chi Square test; P value: P value for Chi Square test; P_A, P_B items: see Additional file 1: Table S1
Predicting Karnofsky score level at each in-person visit using the logistic regression model without interactions
| Variable | Estimate | SE |
|
|---|---|---|---|
| Intercept | 13.19 | 2.79 | < 0.001 |
| Age | 0.08 | 0.01 | < 0.001 |
| Gender (female as Ref.) | 0.21 | 0.14 | 0.124 |
| DM | − 0.05 | 0.32 | 0.875 |
| Primary disease subclass (P_A as Ref.) | − 0.70 | 0.31 | 0.022 |
| Use of vitamin D | − 0.27 | 0.13 | 0.045 |
| Anti-hypertensive agent | − 0.40 | 0.11 | < 0.001 |
| Use of iron | − 0.14 | 0.17 | 0.417 |
| Parathyroidectomy | − 0.02 | 0.17 | 0.910 |
| Treatment of year | − 0.05 | 0.01 | < 0.001 |
| The number of times per week | − 0.57 | 0.18 | 0.002 |
| Each dialysis time | − 0.56 | 0.21 | 0.007 |
| Dialyzer surface area | − 0.95 | 0.22 | < 0.001 |
| Hb | − 0.93 | 0.18 | < 0.001 |
| Hct | 0.33 | 0.06 | < 0.001 |
| WBC | − 0.01 | 0.03 | 0.837 |
| Albumin | − 1.25 | 0.19 | < 0.001 |
| BUN | 0.01 | 4.27E−03 | 0.026 |
| Creatinine | − 0.21 | 0.03 | < 0.001 |
| Ca | 0.03 | 0.07 | 0.669 |
| P | 0.07 | 0.04 | 0.125 |
| Na | − 0.05 | 0.02 | 0.004 |
| K | − 0.42 | 0.08 | < 0.001 |
| Glucose | 2.48E−03 | 9.59E−04 | 0.010 |
| AST | − 0.02 | 0.01 | 0.013 |
| Alkaline P | 2.92E−03 | 1.65E−03 | 0.078 |
| Cholesterol | 1.76E−03 | 1.46E−03 | 0.226 |
| Triglyceride | 4.41E−04 | 6.54E−04 | 0.500 |
| Uric acid | − 0.05 | 0.04 | 0.281 |
| Ferritin | 4.05E−04 | 2.07E−04 | 0.050 |
| Al | − 0.05 | 0.06 | 0.437 |
| iPTH | 2.10E−04 | 1.97E−04 | 0.287 |
| Kt/V | − 0.70 | 0.22 | 0.001 |
| nPCR | 0.24 | 0.24 | 0.327 |
| Ultrafiltration dehydration amount | 0.07 | 0.04 | 0.118 |
| Cardiothoracic ratio | 1.08 | 0.80 | 0.178 |
Predicting Karnofsky score level at each in-person visit using the logistic regression model including selected interaction
| Variable | Estimate | SE |
|
|---|---|---|---|
| Intercept | 2.54 | 6.89 | 0.712 |
| Age | 0.20 | 0.07 | 0.007 |
| Gender (female as Ref.) | 0.25 | 0.14 | 0.075 |
| DM | 0.09 | 0.32 | 0.776 |
| Primary disease subclass (P_A as Ref.) | − 6.18 | 1.12 | < 0.001 |
| Use of vitamin D | − 0.24 | 0.14 | 0.078 |
| Anti-hypertensive agent | − 0.35 | 0.11 | 0.002 |
| Use of iron | − 0.17 | 0.17 | 0.324 |
| Parathyroidectomy | 0.05 | 0.18 | 0.791 |
| Treatment of year | − 0.02 | 0.12 | 0.876 |
| The number of times per week | − 0.52 | 0.18 | 0.005 |
| Each dialysis time | − 0.54 | 0.21 | 0.010 |
| Dialyzer surface area | − 0.93 | 0.23 | < 0.001 |
| Hb | − 0.96 | 0.24 | < 0.001 |
| Hct | 0.32 | 0.06 | < 0.001 |
| WBC | − 0.01 | 0.03 | 0.691 |
| Albumin | 2.14 | 1.62 | 0.188 |
| BUN | 0.01 | 4.32E−03 | 0.039 |
| Creatinine | − 0.01 | 0.38 | 0.972 |
| Ca | 0.04 | 0.07 | 0.590 |
| P | 0.27 | 0.35 | 0.438 |
| Na | − 0.04 | 0.02 | 0.009 |
| K | − 0.42 | 0.08 | < 0.001 |
| Glucose | 2.29E−03 | 9.69E−04 | 0.018 |
| AST | − 0.02 | 0.01 | 0.040 |
| Alkaline P | 2.26E−03 | 1.70E−03 | 0.183 |
| Cholesterol | 1.07E−03 | 1.48E−03 | 0.470 |
| Triglyceride | 5.89E−04 | 6.61E−04 | 0.373 |
| Uric acid | − 0.05 | 0.04 | 0.279 |
| Ferritin | 8.62E−04 | 1.64E−03 | 0.600 |
| Al | − 0.02 | 0.06 | 0.704 |
| iPTH | − 8.04E−04 | 1.46E−03 | 0.581 |
| Kt/V | − 0.75 | 0.23 | 0.001 |
| nPCR | 0.29 | 0.24 | 0.241 |
| Ultrafiltration dehydration amount | 0.08 | 0.05 | 0.093 |
| Cardiothoracic ratio | − 0.10 | 1.07 | 0.923 |
| Age × albumin | − 0.04 | 0.02 | 0.043 |
| Primary disease subclass × age | 0.06 | 0.01 | < 0.001 |
| Primary disease subclass × creatinine | 0.15 | 0.05 | 0.004 |
| Albumin × creatinine | − 0.07 | 0.08 | 0.342 |
| Creatinine × age | 1.41E−03 | 2.85E−03 | 0.620 |
| Creatinine × treatment of year | − 0.02 | 0.01 | 0.004 |
| Age × iPTH | − 1.18E−05 | 1.63E−05 | 0.470 |
| iPTH × cardiothoracic ratio | 3.53E−03 | 2.29E−03 | 0.123 |
| Treatment of year × age | − 2.36E−03 | 1.15E−03 | 0.041 |
| Age × ferritin | − 1.23E−05 | 2.07E−05 | 0.553 |
| Ferritin × P | 7.21E−05 | 1.38E−04 | 0.602 |
| P × Hb | − 0.02 | 0.03 | 0.434 |
| Hb × treatment of year | 0.03 | 0.01 | 0.001 |